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Abstract 
Several studies investigated the potential role of imaging modalities in prostate cancer patients 
in case of biochemical recurrence. However, the role of molecular imaging has not been well 
established yet. Considering the results of the literature and of our own experience, we tried 
to summarize the potential applications of 
11C-choline PET/CT in prostate cancer patients in 
case of biochemical relapse for the detection of lymph node and distant recurrence. 
Key words: prostate cancer; choline PET/CT; restaging. 
Background 
Monitoring Prostate Specific Antigen (PSA) se-
rum level is the best way to follow Prostate Cancer 
(PC) patients after treatment and to detect early re-
currence of the disease [1]. In case of biochemical re-
lapse (PSA>0.2-0.4 ng/mL), Imaging should be able to 
detect  the  site  of  recurrence  in  order  to  establish  a 
correct and tailored therapeutic strategy. It is crucial 
to  distinguish  between  the  presence  of  local  failure 
and/or distant metastasis [2]. The Conventional Im-
aging  (C.I.:  Bone  Scan;  Computed  Tomography  or 
Magnetic Resonance) accuracy is limited in this field 
as reported by many authors [3, 4, 5, 6]. The site of 
distant recurrence, mainly lymph-nodes  or bone  le-
sions,  is  thus,  rarely  detected.  In  the  clinical  daily 
practice it results in an enormous number of negative 
or inconclusive investigations performed in this set-
ting of patients. Choueiri et al [5] tried to identify, in 
292 patients with biochemical failure, clinical param-
eters that were predictive of positive Imaging studies, 
that  could  be  helpful  in  guiding  clinicians  in  their 
requests.  Authors  found  that  age,  imaging  type 
Computed  Tomography  (CT),  Magnetic  Resonace 
(MR),  Bone  scan  (BS),  PSA  and  PSA  doubling  time 
(PSAdt)  were  significantly  associated  with  positive 
imaging results. However, CT, MR and BS were not 
useful when PSA was lower than 5 ng/mL and PSAdt 
greater than 10 months. Summarizing, C.I. showed a 
sensitivity  of  only  11%  (31/292)  with  a  mean  PSA 
value of 23 ng/mL in the group of positive patients. In 
a similar study published by Okotie et al [6], the au-
thors addressed their attention to the influence of PSA 
and PSAdt on CT and BS sensitivity. Bone scan was 
positive in only 11% and CT scan in only 7% of the 
patients.  
The low accuracy shown by C.I. has meant that 
the attention of several authors has been directed to 
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other imaging techniques and molecular imaging in 
particular. 
11C-Choline PET/CT 
The study of tissue metabolism using PET/CT 
could play an important role in this context [7]. In the 
field of prostate cancer, many studies have been ad-
dressed  to  this  aim  in  the  early  past  since  the  first 
study published by Hara et al in 1998 [8] about the 
potential  use  of  11C-choline  in  prostate  cancer  pa-
tients. In this section we will try to highlight the po-
tentials, but also the limitations shown by 11C-choline 
in this field. 
The first large and prospective study was per-
formed by Picchio et al [9] comparing 11C-choline PET 
with  18F-FDG PET results in 100 prostate cancer pa-
tients with a biochemical recurrence (mean PSA value 
6.57  ng/mL).  11C-choline  PET  detected  areas  of  ab-
normal uptake in 47% of patients, while 18F-FDG PET 
in 27% of patients. None of FDG positive was negative 
at  11C-choline. C.I. (BS and MR) were positive in 49 
patients.  The  study  stated  the  utility  of  11C-choline 
PET/CT in the restaging of prostate cancer patients 
after relapse: in particular the authors affirmed that 
11C-choline  PET  resulted  to  be  superior  to  18F-FDG 
PET and complementary to C.I., providing almost the 
same  sensitivity  as  C.I.  but  by  performing  a  single 
examination.  It  is  worth  to  underline  however  that 
this study was performed with PET only scanners and 
not with PET/CT. 
In  the  following  years  many  studies  focused 
their attention to the correlation between the detection 
rate of 11C-choline PET/CT and the serum PSA levels. 
Krause et al [10] evaluated with 11C-choline PET/CT 
sixty-three prostate cancer patients with biochemical 
relapse  after  primary  treatment  (mean  PSA  5,9 
ng/mL). They demonstrated a significant and strict 
correlation  between  11C-choline  PET/CT  detection 
rate and PSA serum levels: the detection rate was 36% 
for a PSA value <1 ng/mL, 43% for a PSA value 1-<2 
ng/mL, 62% for a PSA value 2-<3 ng/mL and 73% for 
a PSA value >or=3 ng/mL. The overall detection rate 
for PET was 59%.  
The influence of other clinical and pathological 
variables also was evaluated in order to better select 
patients which should undergo  11C-choline PET/CT. 
Giovacchini  et  al  [11]  published  the  results  of  their 
investigations on 358 prostate cancer patients (mean 
PSA  3.7  ng/mL):  they  found  that  in  multivariate 
analysis  not  only  PSA  levels,  but  also  advanced 
pathological stage, previous biochemical failure and 
older age (> 65 y) were significantly associated with 
an  increased  risk  of  positive  11C-choline  PET/CT 
findings.  
 In 2009, Castellucci et al [12] for the first time 
investigated  the  relationship  between  11C-choline 
PET/CT  detection  rate  and  other  PSA  derivates  in 
particular PSA kinetics (PSA velocity: PSA vel; PSA 
doubling time: PSAdt). Authors enrolled a total of 190 
patients after radical prostatectomy (RP) who showed 
an  increase  in  PSA  (mean  4.2  ng/mL;  median  2.1 
ng/mL). The study showed an overall detection rate 
of 38.9%. PSA values, PSAdt and PSAvel values were 
the only parameters who showed a statistically sig-
nificant difference between patients with PET-positive 
and  PET-negative  findings.  Authors  conclude  that 
PSA kinetics should always be taken into considera-
tion before performing a  11C-choline PET/CT in pa-
tients with biochemical failure because it is the most 
relevant positive predictive factor. Later on, another 
study by Giovacchini et al [13] confirmed these data. 
They evaluated the influence of PSAdt in 170 patients 
studied  with  11C-choline  PET/CT  after  RP  who 
showed a biochemical failure (mean PSA 3.2 ng/mL). 
The study showed an overall detection rate of 44% 
and an overall accuracy of 88%. Multivariate logistic 
regression  found  that  high  PSA  values  and  short 
PSAdt were the only significant predictors of positive 
11C-choline  PET/CT  scan.  Moreover,  their  results 
demonstrated  that  PSAdt  can  distinguish  between 
patients with pathological  11C-choline uptake in the 
skeleton from patients with pathological  11C-choline 
uptake in the prostatic fossa. Since kinetics of PSA has 
been found to be the most important factor in pre-
dicting a positive 11C-choline PET/CT, Castellucci et 
al [14] have selected a population of 102 consecutive 
patients previously treated with radical prostatecto-
my (RP) and who presented only a mild increase of 
PSA levels <1.5 ng/mL. The aim of the study was to 
determine if 11C-choline PET/CT could be used also in 
patients with low PSA values but fast PSA kinetics, 
i.e. early after biochemical recurrence when the clini-
cal usefulness of the investigation should be maximal. 
Overall,  11C-choline  PET/CT  showed  positive  find-
ings in 29 of 102 patients (28%). What resulted very 
interesting was that the mean PSAdt in PET-positive 
patients was 4.34 months while in PET-negative pa-
tients it  was 13.30 months (p = 0.0001 ). Moreover, 
only  2  out  of  56  patients  (3%)  with  slow  kinetics 
(PSAdt <7.2 months) resulted positive at  11C-choline 
PET/CT versus 27 out of 46 patients (58%) with fast 
kinetics that resulted positive at 11C-choline PET/CT. 
Authors concluded that 11C-choline PET/CT could be 
suggested  early  during  biochemical  relapse  in  pa-
tients presenting with fast PSA kinetics. Fig.1. 
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Fig. 1. 68y.o. patient. Prostate Cancer T3aN1Mx. Biochemical relapse two years after radical prostatectomy. PSA = 1.3 ng/mL at the time 
of 11C-Choline PET/CT. PSAdt = 3 months. 11C-Choline PET /CT detected a single positive lymph-node in the left iliac chain. a) CT images, 
a small sub-centimetric LN is evident in the left iliac chain b) focal increased uptake of 11C-Choline in the left iliac chain c) fused images d) 
MIP. 
 
As  remembered  above  one  of  the  sites  more 
frequently involved by metastatic lesions from pros-
tate cancer is the skeleton. However only few studies 
have performed a direct comparison between the ac-
curacy  of  11C-choline  PET/CT  and  the  one  of  Bone 
Scan in the detection of bone lesions. 
Fuccio  et  al  [15]  studied  with  11C-choline 
PET/CT twenty-five patients who presented a single 
finding that was classified as equivocal or suspected 
for  metastatic  lesion  at  BS.  Authors  found  that 
11C-choline  PET/CT  detected  unknown  lesions  in 
11/25 (44%) patients. Very recently in a larger study, 
Picchio et al [16] studied 78 patients with biochemical 
progression (mean PSA 21.1 ng/ml) with 11C-choline 
PET/CT and BS. Authors found that equivocal find-
ings occurred in only 1 of 78 (1%) cases in 11C-choline 
PET/CT and in 21 of 78 (27%) cases in BS. Depending 
on their attribution as either positive or negative, the 
ranges  of  sensitivity,  specificity,  positive  predictive 
value  (PPV),  negative  predictive  value  (NPV)  and 
accuracy  for  11C-choline  PET/CT  were  89-89%, 
98-100%, 96-100%, 94-96% and 95-96%, respectively. 
For  BS  they  were  100-70%,  75-100%,  68--100%, 
100-86% and 83-90%, respectively. Concordant find-
ings between 11C-choline PET/CT and BS occurred in 
55 of 78 (71%) cases. Fig. 2. Authors conclude that for 
its  high  specificity,  11C-choline  PET/CT  positive 
findings may accurately predict the presence of bone 
metastasis (BM). 
11C-Choline PET/CT guided therapies 
The promising results largely reported in the use 
of  11C-choline  PET/CT  suggested  a  more  extensive 
use  of  such  technique  in  the  clinical  setting. 
11C-choline PET/CT can be used to guide aggressive 
and  tailored  therapies  in  selected  patients,  particu-
larly in those showing few metastatic sites detected by 
11C-choline  PET/CT.  Two  different  approaches  are 
possible:  surgery  (performing  Pelvic  Lymph  Node 
Dissection:  PLND)  or  Radiation  Therapy  (EBRT, 
IMRT). The first study evaluating 11C-choline PET/CT 
as a guide for PLND has been published by Scattoni et 
al. [17] in 25 prostate cancer patients, who resulted to 
be positive at 11C-choline PET/CT (21 pts) or at MR (4 
pts). Mean PSA value was 1.98 ng/mL. Validation of 
results was performed by histology after surgery with 
a mean number of 21.9 nodes per patient removed 
(range:  4–74).  Authors  found  that  19/21  patients 
(90%)  with  positive  11C-choline  PET/CT  had  nodal 
involvement at histological evaluation, while none of Theranostics 2012, 2(3) 
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the 4 patients with negative 11C-choline PET/CT had 
nodal  metastases.  11C-choline  PET/CT  sensitivity, 
specificity, PPV, NPV and accuracy were 64%, 90%, 
86%, 72%, and 77%, respectively. The low NPV seems 
to  depend  on  the  limited  capability  of  11C-choline 
PET/CT  to  detect  micro  metastases.  Very  recently 
Rigatti et al [18] tried to determine whether the re-
moval of positive lymph nodes at 11C-choline PET/CT 
may have an impact on the prognosis of patients with 
nodal recurrence after RP. Authors enrolled prospec-
tively  72  patients  with  no  more  than  2  positive 
lymph-nodes at 11C-choline PET/CT. Results are very 
encouraging  since,  after  a  mean  follow-up  of  39.4 
months,  the  overall  biochemical  response  rate  was 
56.9%.  Preoperative  PSA  <4  ng/mL  and  negative 
lymph nodes at previous RP represented independent 
predictor  of  good  biochemical  response  rate.  These 
data confirm, once more, that the early detection of 
recurrence, when PSA values are low and when met-
astatic diffusion is supposed to be limited, is crucial to 
achieve  response  to  treatment.  Alongi  et  al  [19]  in 
2010, for the first time reported a case of 11C-choline 
PET/CT-guided helical tomotherapy (HTT) concom-
itant with estramustine therapy for the treatment of 
nodal recurrence from prostate cancer in one patient. 
A dose of 67.2Gy was administered in 28 fractions. At 
24 months after the end of helical tomotherapy, PSA 
was undetectable and no late toxicities were recorded. 
Authors underlined that a disease-free survival of 24 
months, in the absence of any type of systemic ther-
apy, is uncommon in metastatic prostate cancer. Very 
recently Souvatsoglu, et al [20] studied the influence 
of 11C-choline PET/CT on the extent of the planning 
target volume (PTV) in thirty-seven patients treated 
with  radical  prostatectomy  and  referred  to  salvage 
radiation therapy (RT) to the prostatic fossa because 
of  biochemical  relapse.  All  patients  underwent 
11C-choline PET/CT before RT. They found that 5/37 
patients  (13%)  had  a  positive  finding  in  the 
11C-choline  PET/CT,  outside  of  the  prostatic  fossa 
(iliac lymph nodes), implicating an extension of the 
PTV. Overall, at the 51 months follow-up, 56% of the 
patients had a PSA < 0.2 ng/mL. 
 
 
 
Fig  2. 76 y.o. patient. Biochemical relapse 9 years after radical prostatectomy. PSA 1,43 ng/mL at the time of the Bone Scan and 
11C-Choline PET/CT. a) The bone scan showed focal uptake in the left clavicle and the right pelvis. b) PET/CT also showed 11C-choline 
uptake in the same > sites, which were evident on CT (pictures c and d). 
 
CONCLUSIONS  
In summary, considering the previous literature 
and  our  own  experience,  we  can  conclude  that 
11C-choline  PET/CT  could  represent  an  important 
imaging modality in the detection of distant relapses 
in  prostate  cancer  patients  with  biochemical  recur-
rence. According to these data,  11C-choline PET/CT 
could play a crucial role as first diagnostic procedure 
in patients at high risk of relapse who demonstrate a 
fast PSA kinetics, even in presence of low PSA values. 
11C-choline PET/CT should be more extensively used 
mostly in order to address guided therapies such as 
RT (either EBRT, IMRT or Hormonal Treatment) or Theranostics 2012, 2(3) 
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surgery  with  PLND.  The  results  of  the  few  studies 
published  so  far  are  very  encouraging,  since  about 
half of the patients are free from relapse (either bio-
chemical  or  clinical)  for  a  significant  number  of 
months. This could reduce the use of anti androgenic 
treatments with a significant benefit to the patients in 
terms of reduction of side effects and, probably, with 
a  significant  reduction  in  costs.  Larger  studies  are 
needed to confirm these hypothesis. 
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